Specific inhibitors of p110α, but not inhibitors of p110β p110γ, or p110δ abolished the phenotypic effects of two of these tumour-derived mutant forms (KS459delN, DKRMNS560del), indicating that the oncogenic activity of these mutants is uniquely mediated by p110α. The gene discussed is PIK3CD; the disease is neoplasm.